首页 > 最新文献

Current Research in Pharmacology and Drug Discovery最新文献

英文 中文
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies 针对乳腺癌中的 c-Met:从化疗抗药性机制到新型治疗策略
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100204
Emeka Eze Joshua Iweala , Doris Nnenna Amuji , Abimbola Mary Oluwajembola , Eziuche Amadike Ugbogu
Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemoresistance, particularly in the triple-negative subtype. c-Mesenchymal epithelial transition factor (c-Met), a receptor tyrosine kinase, presents a promising target for breast cancer therapy due to its involvement in disease progression and poor prognosis. However, the heterogeneous expression of c-Met within breast cancer subtypes and individual tumors complicates targeted therapy. Also, cancer cells can develop resistance to c-Met inhibitors through various mechanisms, including bypass signaling pathways and genetic mutations. The off-target effects of c-Met inhibitors further limit their clinical utility, necessitating the development of more selective agents. To overcome these challenges, personalized treatment approaches and combination therapies are being explored to improve treatment efficacy while minimizing adverse effects. Novel c-Met inhibitors with improved selectivity and reduced off-target toxicity show promise in preclinical studies. Additionally, targeted delivery systems aim to enhance drug localization and reduce systemic toxicity. Future directions involve refining inhibitor design and integrating c-Met inhibition into personalized treatment regimens guided by molecular profiling. This review explores the mechanisms by which c-Met contributes to chemoresistance in breast cancer and current challenges in targeting c-Met for breast cancer therapy. It discusses strategies to optimize treatment outcomes, ultimately improving patient prognosis and reducing mortality rates associated with this devastating disease.
c-间质上皮转化因子(c-Met)是一种受体酪氨酸激酶,因其参与疾病进展和不良预后而成为乳腺癌治疗的一个有希望的靶点。然而,c-Met 在乳腺癌亚型和单个肿瘤中的异质性表达使靶向治疗变得复杂。此外,癌细胞可通过各种机制(包括旁路信号通路和基因突变)对 c-Met 抑制剂产生抗药性。c-Met 抑制剂的脱靶效应进一步限制了其临床应用,因此有必要开发更具选择性的药物。为了克服这些挑战,目前正在探索个性化治疗方法和联合疗法,以提高疗效,同时尽量减少不良反应。临床前研究显示,新型 c-Met 抑制剂具有更好的选择性和更低的脱靶毒性。此外,靶向给药系统旨在加强药物定位并减少全身毒性。未来的研究方向包括完善抑制剂设计,并将 c-Met 抑制纳入以分子谱分析为指导的个性化治疗方案。这篇综述探讨了 c-Met 导致乳腺癌化疗耐药的机制,以及目前针对 c-Met 治疗乳腺癌所面临的挑战。它讨论了优化治疗效果的策略,最终改善患者的预后,降低与这种毁灭性疾病相关的死亡率。
{"title":"Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies","authors":"Emeka Eze Joshua Iweala ,&nbsp;Doris Nnenna Amuji ,&nbsp;Abimbola Mary Oluwajembola ,&nbsp;Eziuche Amadike Ugbogu","doi":"10.1016/j.crphar.2024.100204","DOIUrl":"10.1016/j.crphar.2024.100204","url":null,"abstract":"<div><div>Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemoresistance, particularly in the triple-negative subtype. c-Mesenchymal epithelial transition factor (c-Met), a receptor tyrosine kinase, presents a promising target for breast cancer therapy due to its involvement in disease progression and poor prognosis. However, the heterogeneous expression of c-Met within breast cancer subtypes and individual tumors complicates targeted therapy. Also, cancer cells can develop resistance to c-Met inhibitors through various mechanisms, including bypass signaling pathways and genetic mutations. The off-target effects of c-Met inhibitors further limit their clinical utility, necessitating the development of more selective agents. To overcome these challenges, personalized treatment approaches and combination therapies are being explored to improve treatment efficacy while minimizing adverse effects. Novel c-Met inhibitors with improved selectivity and reduced off-target toxicity show promise in preclinical studies. Additionally, targeted delivery systems aim to enhance drug localization and reduce systemic toxicity. Future directions involve refining inhibitor design and integrating c-Met inhibition into personalized treatment regimens guided by molecular profiling. This review explores the mechanisms by which c-Met contributes to chemoresistance in breast cancer and current challenges in targeting c-Met for breast cancer therapy. It discusses strategies to optimize treatment outcomes, ultimately improving patient prognosis and reducing mortality rates associated with this devastating disease.</div></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"7 ","pages":"Article 100204"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet 利拉鲁肽可改善高脂饮食诱导的内脏肥胖模型中的脂肪组织重塑和线粒体动力学。
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100185
Vanessa Touceda , Florencia Fontana Estevez , Leonardo Cacciagiú , Paola Finocchietto , Romina Bustos , Agustina Vidal , Gabriela Berg , Celina Morales , Germán González , Veronica Miksztowicz

Central obesity is characterized by visceral adipose tissue (VAT) expansion, considered one of the main risk factors for metabolic complications. In recent years, new drugs have been studied for obesity treatment. Liraglutide (LGT), a GLP-1 agonist, decreases body weight, however, several mechanisms of action on VAT are still unknown.

Aim

to study the effect of LGT on factors associated with VAT remodeling and mitochondrial dynamics in mice fed a high-fat diet (HFD).

Methods

C57BL/6 mice were divided into Control (C) and HFD. After 15 weeks of feeding, each group was subdivided according to LGT administration for 5 weeks: C, C + LGT, HFD, and HFD + LGT. In epididymal AT (EAT) we evaluated histological and mitochondrial characteristics, vascularity, gelatinase activity (MMPs), and galectin-3 expression.

Results

HFD presented larger adipocytes (p < 0.05), and lower vascular density and MMP-9 activity (p < 0.01) than C, while a major number of smaller adipocytes (p < 0.05) and an increase in vascularity (p < 0.001) and MMP-9 activity (p < 0.01) was observed in HFD + LGT. Collagen content was higher (p < 0.05) in EAT from HFD and decreased in HFD + LGT. In C, C + LGT, and HFD + LGT, mitochondria were predominantly tubular-shaped while in HFD mitochondria were mostly spherical (p < 0.001).

Conclusion

LGT positively influences VAT behavior by modulating gelatinase activity, enhancing vascularization, and improving adipocyte histological characteristics. Additionally, LGT improves mitochondrial dynamics, a process that would favor VAT functionality.

中心性肥胖的特点是内脏脂肪组织(VAT)膨胀,被认为是代谢并发症的主要风险因素之一。近年来,人们开始研究治疗肥胖症的新药物。方法将 C57BL/6 小鼠分为对照组(C)和高脂饮食组(HFD)。喂养 15 周后,根据 LGT 给药情况将每组小鼠细分为 5 周:C、C + LGT、HFD 和 HFD + LGT。在附睾AT(EAT)中,我们评估了组织学和线粒体特征、血管、明胶酶活性(MMPs)和galectin-3的表达。05),血管密度和 MMP-9 活性(p <;0.01)比 C 低,而在 HFD + LGT 中观察到较小脂肪细胞数量较多(p <;0.05),血管密度(p <;0.001)和 MMP-9 活性(p <;0.01)增加。HFD + LGT 的 EAT 中胶原蛋白含量较高(p < 0.05),而 HFD + LGT 的 EAT 中胶原蛋白含量较低。在 C、C + LGT 和 HFD + LGT 中,线粒体主要呈管状,而在 HFD 中线粒体主要呈球状(p < 0.001)。此外,LGT 还能改善线粒体动力学,这一过程将有利于 VAT 功能的发挥。
{"title":"Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet","authors":"Vanessa Touceda ,&nbsp;Florencia Fontana Estevez ,&nbsp;Leonardo Cacciagiú ,&nbsp;Paola Finocchietto ,&nbsp;Romina Bustos ,&nbsp;Agustina Vidal ,&nbsp;Gabriela Berg ,&nbsp;Celina Morales ,&nbsp;Germán González ,&nbsp;Veronica Miksztowicz","doi":"10.1016/j.crphar.2024.100185","DOIUrl":"10.1016/j.crphar.2024.100185","url":null,"abstract":"<div><p>Central obesity is characterized by visceral adipose tissue (VAT) expansion, considered one of the main risk factors for metabolic complications. In recent years, new drugs have been studied for obesity treatment. Liraglutide (LGT), a GLP-1 agonist, decreases body weight, however, several mechanisms of action on VAT are still unknown.</p></div><div><h3>Aim</h3><p>to study the effect of LGT on factors associated with VAT remodeling and mitochondrial dynamics in mice fed a high-fat diet (HFD).</p></div><div><h3>Methods</h3><p>C57BL/6 mice were divided into Control (C) and HFD. After 15 weeks of feeding, each group was subdivided according to LGT administration for 5 weeks: C, C + LGT, HFD, and HFD + LGT. In epididymal AT (EAT) we evaluated histological and mitochondrial characteristics, vascularity, gelatinase activity (MMPs), and galectin-3 expression.</p></div><div><h3>Results</h3><p>HFD presented larger adipocytes (p &lt; 0.05), and lower vascular density and MMP-9 activity (p &lt; 0.01) than C, while a major number of smaller adipocytes (p &lt; 0.05) and an increase in vascularity (p &lt; 0.001) and MMP-9 activity (p &lt; 0.01) was observed in HFD + LGT. Collagen content was higher (p &lt; 0.05) in EAT from HFD and decreased in HFD + LGT. In C, C + LGT, and HFD + LGT, mitochondria were predominantly tubular-shaped while in HFD mitochondria were mostly spherical (p &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>LGT positively influences VAT behavior by modulating gelatinase activity, enhancing vascularization, and improving adipocyte histological characteristics. Additionally, LGT improves mitochondrial dynamics, a process that would favor VAT functionality.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"6 ","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000129/pdfft?md5=2d5a86602bcffd980508a12e69fbcb26&pid=1-s2.0-S2590257124000129-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential of miRNA-based approaches in glioblastoma: An update in current advances and future perspectives 基于 miRNA 的胶质母细胞瘤治疗方法的潜力:最新进展与未来展望
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100193
Edgar G. Ordóñez-Rubiano MD, PhD (c) , Nicolás Rincón-Arias MD , Sebastian Espinosa MD , William J. Shelton MD , Andres F. Salazar , Alba Cómbita MSc, PhD , Matías Baldoncini MD , Sabino Luzzi MD, PhD , César Payán-Gómez MD, PhD , Diego F. Gómez- Amarillo MD, MSc , Fernando Hakim MD , Javier G. Patiño-Gómez MD , Rafael Parra- Medina MD, PhD

Glioblastoma (GBM) is the most common malignant central nervous system tumor. The emerging field of epigenetics stands out as particularly promising. Notably, the discovery of micro RNAs (miRNAs) has paved the way for advancements in diagnosing, treating, and prognosticating patients with brain tumors. We aim to provide an overview of the emergence of miRNAs in GBM and their potential role in the multifaceted management of this disease. We discuss the current state of the art regarding miRNAs and GBM. We performed a narrative review using the MEDLINE/PUBMED database to retrieve peer-reviewed articles related to the use of miRNA approaches for the treatment of GBMs. MiRNAs are intrinsic non-coding RNA molecules that regulate gene expression mainly through post-transcriptional mechanisms. The deregulation of some of these molecules is related to the pathogenesis of GBM. The inclusion of molecular characterization for the diagnosis of brain tumors and the advent of less-invasive diagnostic methods such as liquid biopsies, highlights the potential of these molecules as biomarkers for guiding the management of brain tumors such as GBM. Importantly, there is a need for more studies to better examine the application of these novel molecules. The constantly changing characterization and approach to the diagnosis and management of brain tumors broaden the possibilities for the molecular inclusion of novel epigenetic molecules, such as miRNAs, for a better understanding of this disease.

胶质母细胞瘤(GBM)是最常见的恶性中枢神经系统肿瘤。新兴的表观遗传学领域前景尤为广阔。值得注意的是,微小核糖核酸(miRNA)的发现为脑肿瘤患者的诊断、治疗和预后判断铺平了道路。我们旨在概述 miRNAs 在 GBM 中的出现及其在该疾病多方面治疗中的潜在作用。我们讨论了有关 miRNA 和 GBM 的最新研究进展。我们利用 MEDLINE/PUBMED 数据库检索了与使用 miRNA 方法治疗 GBM 相关的同行评议文章,并进行了叙述性综述。MiRNA 是内在的非编码 RNA 分子,主要通过转录后机制调控基因表达。其中一些分子的失调与 GBM 的发病机制有关。将分子特征纳入脑肿瘤诊断以及液体活检等微创诊断方法的出现,凸显了这些分子作为生物标志物指导 GBM 等脑肿瘤治疗的潜力。重要的是,需要进行更多的研究,以更好地检查这些新型分子的应用情况。脑肿瘤不断变化的特征和诊断与管理方法拓宽了分子纳入新型表观遗传分子(如 miRNA)的可能性,以更好地了解这种疾病。
{"title":"The potential of miRNA-based approaches in glioblastoma: An update in current advances and future perspectives","authors":"Edgar G. Ordóñez-Rubiano MD, PhD (c) ,&nbsp;Nicolás Rincón-Arias MD ,&nbsp;Sebastian Espinosa MD ,&nbsp;William J. Shelton MD ,&nbsp;Andres F. Salazar ,&nbsp;Alba Cómbita MSc, PhD ,&nbsp;Matías Baldoncini MD ,&nbsp;Sabino Luzzi MD, PhD ,&nbsp;César Payán-Gómez MD, PhD ,&nbsp;Diego F. Gómez- Amarillo MD, MSc ,&nbsp;Fernando Hakim MD ,&nbsp;Javier G. Patiño-Gómez MD ,&nbsp;Rafael Parra- Medina MD, PhD","doi":"10.1016/j.crphar.2024.100193","DOIUrl":"https://doi.org/10.1016/j.crphar.2024.100193","url":null,"abstract":"<div><p>Glioblastoma (GBM) is the most common malignant central nervous system tumor. The emerging field of epigenetics stands out as particularly promising. Notably, the discovery of micro RNAs (miRNAs) has paved the way for advancements in diagnosing, treating, and prognosticating patients with brain tumors. We aim to provide an overview of the emergence of miRNAs in GBM and their potential role in the multifaceted management of this disease. We discuss the current state of the art regarding miRNAs and GBM. We performed a narrative review using the MEDLINE/PUBMED database to retrieve peer-reviewed articles related to the use of miRNA approaches for the treatment of GBMs. MiRNAs are intrinsic non-coding RNA molecules that regulate gene expression mainly through post-transcriptional mechanisms. The deregulation of some of these molecules is related to the pathogenesis of GBM. The inclusion of molecular characterization for the diagnosis of brain tumors and the advent of less-invasive diagnostic methods such as liquid biopsies, highlights the potential of these molecules as biomarkers for guiding the management of brain tumors such as GBM. Importantly, there is a need for more studies to better examine the application of these novel molecules. The constantly changing characterization and approach to the diagnosis and management of brain tumors broaden the possibilities for the molecular inclusion of novel epigenetic molecules, such as miRNAs, for a better understanding of this disease.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"7 ","pages":"Article 100193"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000208/pdfft?md5=e3fb5cee84b6f649ec2a936785e8f6e2&pid=1-s2.0-S2590257124000208-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Recombinant Antibody by Yeast Surface Display Technology 利用酵母表面展示技术开发重组抗体
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100174
Mujahed I. Mustafa , Awad A. Alzebair , Ahmed Mohammed

Recombinant antibodies have emerged as powerful tools in various fields, including therapeutics, diagnostics, and research applications. The selection of high-affinity antibodies with desired specificity is a crucial step in the development of recombinant antibody-based products. In recent years, yeast surface display technology has gained significant attention as a robust and versatile platform for antibody selection. This graphical review provides an overview of the yeast surface display technology and its applications in recombinant antibody selection. We discuss the key components involved in the construction of yeast surface display libraries, including the antibody gene libraries, yeast host strains, and display vectors. Furthermore, we highlight the strategies employed for affinity maturation and optimization of recombinant antibodies using yeast surface display. Finally, we discuss the advantages and limitations of this technology compared to other antibody selection methods. Overall, yeast surface display technology offers a powerful and efficient approach for the selection of recombinant antibodies, enabling the rapid generation of high-affinity antibodies for various applications.

重组抗体已成为治疗、诊断和研究应用等各个领域的强大工具。选择具有所需特异性的高亲和力抗体是开发基于重组抗体的产品的关键步骤。近年来,酵母表面展示技术作为一种强大的多功能抗体筛选平台受到了广泛关注。本图解综述概述了酵母表面展示技术及其在重组抗体筛选中的应用。我们讨论了构建酵母表面展示文库的关键组成部分,包括抗体基因文库、酵母宿主菌株和展示载体。此外,我们还重点介绍了利用酵母表面展示技术进行亲和力成熟和重组抗体优化的策略。最后,我们讨论了该技术与其他抗体筛选方法相比的优势和局限性。总之,酵母表面展示技术为重组抗体的筛选提供了一种强大而高效的方法,能快速产生用于各种应用的高亲和力抗体。
{"title":"Development of Recombinant Antibody by Yeast Surface Display Technology","authors":"Mujahed I. Mustafa ,&nbsp;Awad A. Alzebair ,&nbsp;Ahmed Mohammed","doi":"10.1016/j.crphar.2024.100174","DOIUrl":"10.1016/j.crphar.2024.100174","url":null,"abstract":"<div><p>Recombinant antibodies have emerged as powerful tools in various fields, including therapeutics, diagnostics, and research applications. The selection of high-affinity antibodies with desired specificity is a crucial step in the development of recombinant antibody-based products. In recent years, yeast surface display technology has gained significant attention as a robust and versatile platform for antibody selection. This graphical review provides an overview of the yeast surface display technology and its applications in recombinant antibody selection. We discuss the key components involved in the construction of yeast surface display libraries, including the antibody gene libraries, yeast host strains, and display vectors. Furthermore, we highlight the strategies employed for affinity maturation and optimization of recombinant antibodies using yeast surface display. Finally, we discuss the advantages and limitations of this technology compared to other antibody selection methods. Overall, yeast surface display technology offers a powerful and efficient approach for the selection of recombinant antibodies, enabling the rapid generation of high-affinity antibodies for various applications.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"6 ","pages":"Article 100174"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000014/pdfft?md5=6b65539c630be8a3142504caae389fe9&pid=1-s2.0-S2590257124000014-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement 用于治疗慢性阻塞性肺疾病的新型吸入式 PDE3 和 PDE4 双抑制剂安西芬净:根据 PRISMA 声明对低谷 FEV1 和病情恶化进行的系统综述和荟萃分析方案
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100195
Luigino Calzetta , Mario Cazzola , Shima Gholamalishahi , Paola Rogliani

The investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its therapeutic efficacy in COPD is lacking. This protocol outlines the first registered systematic review and meta-analysis in PROSPERO to assess the impact of ensifentrine on trough forced expiratory volume in the 1st second (FEV1) and acute exacerbations of COPD. By conducting a rigorous literature search and employing solid methodologies, this endeavour aims to provide robust evidence on the real efficacy of ensifentrine. Anticipated outcomes include a significant improvement in trough FEV1 and a reduction in AECOPD risk among ensifentrine-treated patients compared to controls, corroborating its bronchodilator and anti-inflammatory properties. The meta-analysis expects to reveal consistent results across different trials, enhancing confidence in the findings. Additionally, subgroup analyses may unveil factors influencing the efficacy of ensifentrine, guiding optimal therapeutic strategies. Overall, this protocol holds the potential to inform clinical practice and regulatory decisions, positioning ensifentrine as a valuable addition to COPD management.

吸入性磷酸二酯酶(PDE)3 和 PDE4 双抑制剂安非他酮用于慢性阻塞性肺病(COPD)维持治疗的研究引起了极大的临床兴趣。尽管最近的 III 期试验取得了令人鼓舞的结果,但仍缺乏对其在慢性阻塞性肺病中疗效的全面综述。本方案概述了 PROSPERO 中首次登记的系统综述和荟萃分析,以评估安非他酮对第一秒用力呼气容积(FEV1)谷值和慢性阻塞性肺疾病急性加重的影响。通过进行严格的文献检索和采用可靠的方法,这项工作旨在为安昔喷丁的实际疗效提供有力的证据。预期结果包括:与对照组相比,接受安非他酮治疗的患者的 FEV1 谷值明显改善,AECOPD 风险降低,证实了其支气管扩张和抗炎特性。荟萃分析有望揭示不同试验的一致结果,从而增强对研究结果的信心。此外,亚组分析可能会揭示影响安塞芬净疗效的因素,从而指导最佳治疗策略。总之,该方案有望为临床实践和监管决策提供依据,并将安非他酮定位为慢性阻塞性肺疾病治疗的重要补充药物。
{"title":"The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement","authors":"Luigino Calzetta ,&nbsp;Mario Cazzola ,&nbsp;Shima Gholamalishahi ,&nbsp;Paola Rogliani","doi":"10.1016/j.crphar.2024.100195","DOIUrl":"https://doi.org/10.1016/j.crphar.2024.100195","url":null,"abstract":"<div><p>The investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its therapeutic efficacy in COPD is lacking. This protocol outlines the first registered systematic review and meta-analysis in PROSPERO to assess the impact of ensifentrine on trough forced expiratory volume in the 1st second (FEV<sub>1</sub>) and acute exacerbations of COPD. By conducting a rigorous literature search and employing solid methodologies, this endeavour aims to provide robust evidence on the real efficacy of ensifentrine. Anticipated outcomes include a significant improvement in trough FEV<sub>1</sub> and a reduction in AECOPD risk among ensifentrine-treated patients compared to controls, corroborating its bronchodilator and anti-inflammatory properties. The meta-analysis expects to reveal consistent results across different trials, enhancing confidence in the findings. Additionally, subgroup analyses may unveil factors influencing the efficacy of ensifentrine, guiding optimal therapeutic strategies. Overall, this protocol holds the potential to inform clinical practice and regulatory decisions, positioning ensifentrine as a valuable addition to COPD management.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"7 ","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000221/pdfft?md5=c1dd1dd9bb8e3d2305050b6a5ff9b591&pid=1-s2.0-S2590257124000221-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stem cell therapy as a promising approach for ischemic stroke treatment 干细胞疗法是治疗缺血性中风的有效方法
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100183
Sahar Yaqubi, Mohammad Karimian

Ischemia as the most common type of stroke is the main cause of death and disability in the world. However, there are few therapeutic approaches to treat ischemic stroke. The common approach to the treatment of ischemia includes surgery-cum-chemical drugs. Surgery and chemical drugs are used to remove blood clots to prevent the deterioration of the nervous system. Given the surgical hazards and the challenges associated with chemical drugs, these cannot be considered safe approaches to the treatment of brain ischemia. Besides surgery-cum-chemical drugs, different types of stem cells including mesenchymal stem cells and neurological stem cells have been considered to treat ischemic stroke. Therapeutic approaches utilizing stem cells to treat strokes are promising because of their neuroprotective and regenerative benefits. However, the mechanisms by which the transplanted stem cells perform their precisely actions are unknown. The purpose of this study is to critically review stem cell-based therapeutic approaches for ischemia along with related challenges.

缺血性中风是最常见的中风类型,也是世界上导致死亡和残疾的主要原因。然而,治疗缺血性中风的方法很少。治疗缺血性中风的常用方法包括手术和化学药物。手术和化学药物用于清除血凝块,防止神经系统恶化。鉴于手术的危险性和化学药物带来的挑战,这些都不能被视为治疗脑缺血的安全方法。除了手术和化学药物外,不同类型的干细胞(包括间充质干细胞和神经干细胞)也被用来治疗缺血性中风。利用干细胞治疗中风的方法很有前景,因为干细胞具有神经保护和再生功能。然而,移植干细胞发挥精确作用的机制尚不清楚。本研究的目的是对基于干细胞的缺血治疗方法及相关挑战进行批判性回顾。
{"title":"Stem cell therapy as a promising approach for ischemic stroke treatment","authors":"Sahar Yaqubi,&nbsp;Mohammad Karimian","doi":"10.1016/j.crphar.2024.100183","DOIUrl":"10.1016/j.crphar.2024.100183","url":null,"abstract":"<div><p>Ischemia as the most common type of stroke is the main cause of death and disability in the world. However, there are few therapeutic approaches to treat ischemic stroke. The common approach to the treatment of ischemia includes surgery-cum-chemical drugs. Surgery and chemical drugs are used to remove blood clots to prevent the deterioration of the nervous system. Given the surgical hazards and the challenges associated with chemical drugs, these cannot be considered safe approaches to the treatment of brain ischemia. Besides surgery-cum-chemical drugs, different types of stem cells including mesenchymal stem cells and neurological stem cells have been considered to treat ischemic stroke. Therapeutic approaches utilizing stem cells to treat strokes are promising because of their neuroprotective and regenerative benefits. However, the mechanisms by which the transplanted stem cells perform their precisely actions are unknown. The purpose of this study is to critically review stem cell-based therapeutic approaches for ischemia along with related challenges.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"6 ","pages":"Article 100183"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000105/pdfft?md5=4930984c2fd48472ce800fface90619c&pid=1-s2.0-S2590257124000105-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141032993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of 2-((4-(chloromethyl)benzoyl)oxy)benzoate acid for analgesic tablet dosage form formulation 用于镇痛片剂配方的 2-((4-(氯甲基)苯甲酰基)氧基)苯甲酸的表征
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100200
Wuryanto Hadinugroho, Yudy Tjahjono, Kuncoro Foe, Senny Yesery Esar, Caroline Caroline, Maria Annabella Jessica, Hendy Wijaya

The 2-((4-(chloromethyl)benzoyl)oxy)benzoic acid (4CH2Cl) is a potential analgesic compound derived from salicylic acid and 4-chloromethyl benzoyl chloride. Characterization required 4CH2Cl for the formulation of tablet dosage forms. This study aims investigate the effect of SSG, PVP-K30, and the combination of SSG*PVP K-30 on the formulation of 4CH2Cl tablets. Additionally, this study aimed to obtain the optimum 4CH2Cl tablet composition. The experiment followed the two-factor simplex lattice design and direct compression method. The analgesic activity of 4CH2Cl in the optimal tablet was investigated using the hot-plate methods. The ANOVA of linear models is acceptable and the polynomial coefficients of quadratic models are similar to those of linear models. The coefficient of the linear model shows that SSG and PVP K-30 increase the Carr index (16.26; 20.61), Hausner ratio (1.19; 1.29), hardness (4.19; 9.39), friability (0.48; 0.67), disintegration time (0.34; 7.50), and drug release (85.29; 97.69). The coefficient of the quadratic model shows that SSG*PVP K-30 increased the Carr index (1.90), Hausner ratio (0.04), hardness (1.88), friability (0.06), and drug release (4.56), and decreased disintegration time (−0.30). SSG and PVP K-30 increased Carr index, Hausner ratio, hardness, friability, disintegration time, and drug release. The combination of SSG*PVP K-30 has the same effect, except that the disintegration time decreased. The optimum tablet formula is 4CH2Cl (300 mg), Ne (75 mg), SSG (33.60 mg), PVP K-30 (22.40 mg), MCC (40 mg), and SDL (up to 800 mg). 4CH2Cl tablets can be a candidate and choice for new analgesic drugs in the future.

2-((4-(氯甲基)苯甲酰基)氧基)苯甲酸(4CH2Cl)是一种潜在的镇痛化合物,由水杨酸和 4-氯甲基苯甲酰氯衍生而来。制备片剂需要 4CH2Cl 的特性。本研究旨在探讨 SSG、PVP-K30 以及 SSG*PVP K-30 组合对 4CH2Cl 片剂配方的影响。此外,本研究还旨在获得最佳的 4CH2Cl 片剂成分。实验采用了双因素简格设计和直接压片法。采用热板法研究了最佳片剂中 4CH2Cl 的镇痛活性。线性模型的方差分析是可以接受的,二次模型的多项式系数与线性模型相似。线性模型的系数表明,SSG 和 PVP K-30 增加了卡尔指数(16.26;20.61)、豪斯纳比率(1.19;1.29)、硬度(4.19;9.39)、易碎性(0.48;0.67)、崩解时间(0.34;7.50)和药物释放(85.29;97.69)。二次模型系数显示,SSG*PVP K-30 增加了 Carr 指数(1.90)、豪斯纳比率(0.04)、硬度(1.88)、易碎性(0.06)和药物释放(4.56),减少了崩解时间(-0.30)。SSG 和 PVP K-30 增加了卡尔指数、豪斯纳比率、硬度、易碎性、崩解时间和药物释放。SSG*PVP K-30 的组合效果相同,只是崩解时间缩短。最佳片剂配方为:4CH2Cl(300 毫克)、Ne(75 毫克)、SSG(33.60 毫克)、PVP K-30(22.40 毫克)、MCC(40 毫克)和 SDL(最多 800 毫克)。4CH2Cl 片剂可作为未来新型镇痛药物的候选和选择。
{"title":"Characterization of 2-((4-(chloromethyl)benzoyl)oxy)benzoate acid for analgesic tablet dosage form formulation","authors":"Wuryanto Hadinugroho,&nbsp;Yudy Tjahjono,&nbsp;Kuncoro Foe,&nbsp;Senny Yesery Esar,&nbsp;Caroline Caroline,&nbsp;Maria Annabella Jessica,&nbsp;Hendy Wijaya","doi":"10.1016/j.crphar.2024.100200","DOIUrl":"10.1016/j.crphar.2024.100200","url":null,"abstract":"<div><p>The 2-((4-(chloromethyl)benzoyl)oxy)benzoic acid (4CH<sub>2</sub>Cl) is a potential analgesic compound derived from salicylic acid and 4-chloromethyl benzoyl chloride. Characterization required 4CH<sub>2</sub>Cl for the formulation of tablet dosage forms. This study aims investigate the effect of SSG, PVP-K30, and the combination of SSG*PVP K-30 on the formulation of 4CH<sub>2</sub>Cl tablets. Additionally, this study aimed to obtain the optimum 4CH<sub>2</sub>Cl tablet composition. The experiment followed the two-factor simplex lattice design and direct compression method. The analgesic activity of 4CH<sub>2</sub>Cl in the optimal tablet was investigated using the hot-plate methods. The ANOVA of linear models is acceptable and the polynomial coefficients of quadratic models are similar to those of linear models. The coefficient of the linear model shows that SSG and PVP K-30 increase the Carr index (16.26; 20.61), Hausner ratio (1.19; 1.29), hardness (4.19; 9.39), friability (0.48; 0.67), disintegration time (0.34; 7.50), and drug release (85.29; 97.69). The coefficient of the quadratic model shows that SSG*PVP K-30 increased the Carr index (1.90), Hausner ratio (0.04), hardness (1.88), friability (0.06), and drug release (4.56), and decreased disintegration time (−0.30). SSG and PVP K-30 increased Carr index, Hausner ratio, hardness, friability, disintegration time, and drug release. The combination of SSG*PVP K-30 has the same effect, except that the disintegration time decreased. The optimum tablet formula is 4CH<sub>2</sub>Cl (300 mg), Ne (75 mg), SSG (33.60 mg), PVP K-30 (22.40 mg), MCC (40 mg), and SDL (up to 800 mg). 4CH<sub>2</sub>Cl tablets can be a candidate and choice for new analgesic drugs in the future.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"7 ","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000270/pdfft?md5=a80324e5d165886f3005648cc749103b&pid=1-s2.0-S2590257124000270-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Papaverine attenuates the progression of alpha naphthylisothiocyanate induce cholestasis in rats 木蝴蝶碱可减轻α-萘基异硫氰酸盐诱导大鼠胆汁淤积症的进展
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100177
Doaa Adnan Atshan , Munaf Hashim Zalzala

Cholestasis is a hepatobiliary condition that manifests as acute or chronic and results from disruptions in the bile flow, formation, or secretion processes. The Farnesoid X receptor (FXR) is a vital target for the therapy of cholestasis since it regulates BA homeostasis. Despite the discovery of multiple active FXR agonists, there are still no effective treatments for cholestasis. Papaverine is identified as an FXR agonist.This study investigates papaverine's efficacy and probable mechanism in protecting against alpha naphthylisothiocyanate (ANIT) induced cholestasis. Thirty male albino rats were divided into three groups, each with ten rats. Group I (control) rats were administered 1 mL/kg corn oil 48 h before sacrifice; group II rats were orally administered 100 mg/kg ANIT. Group III received a 200 mg/kg dosage of papaverine over seven consecutive days. A single dose of ANIT at a concentration of 100 mg/kg was orally administered on the fifth day; group II and III animals were euthanized 48 h after inducing cholestasis, and serum concentrations of liver function tests and total bile acid (TBA) were measured. Besides measuring the inflammatory mediator's tumor necrosis factor-alpha (TNF-α) and interleukin 1 (IL-1β), antioxidant markers such as superoxide dismutase (SOD) and glutathione (GSH) were also assessed. The findings indicated the enhancement in the liver function test and total bile acids, as well as in liver histology; papaverine significantly lowered TNF-α and IL-1β while SOD and GSH significantly increased. Additionally, papaverine upregulates Fxr gene expression, bile salt export pump (Besp), small heterodimer partner (shp), hepatocyte nuclear factor 1α (Hnfα), nuclear factor erythroid 2-related factor (Nrf2), heme oxygenase (Ho-1), NAD(P)H quinone oxidoreductase 1 (Nqo1). Furthermore, papaverine increased protein expressions of Sirtuin1.

(SIRT 1), FXR, HO-1, and BSEP levels in the rats' livers. The protective effects of papaverine may be attributed to the activation of FXR signaling pathways. These findings revealed that papaverine protects against ANIT-induced Cholestasis.

胆汁淤积症是一种肝胆疾病,可表现为急性或慢性,是胆汁流动、形成或分泌过程紊乱的结果。法尼类固醇 X 受体(FXR)是治疗胆汁淤积症的重要靶点,因为它能调节胆汁酸的平衡。尽管发现了多种活性 FXR 激动剂,但胆汁淤积症仍然没有有效的治疗方法。本研究探讨了木蝴蝶碱在抗α-萘基异硫氰酸盐(ANIT)诱导的胆汁淤积症方面的功效和可能机制。30 只雄性白化大鼠被分为三组,每组 10 只。第一组(对照组)大鼠在牺牲前 48 小时服用 1 毫升/千克玉米油;第二组大鼠口服 100 毫克/千克 ANIT。第三组连续七天服用 200 毫克/千克的罂粟碱。第五天口服单剂量浓度为 100 毫克/千克的 ANIT;诱导胆汁淤积 48 小时后,对 II 组和 III 组动物实施安乐死,并测量血清中的肝功能检测指标和总胆汁酸(TBA)浓度。除了检测炎症介质肿瘤坏死因子α(TNF-α)和白细胞介素1(IL-1β)外,还评估了超氧化物歧化酶(SOD)和谷胱甘肽(GSH)等抗氧化指标。研究结果表明,肝功能测试和总胆汁酸以及肝组织学均有改善;木瓜碱显著降低了 TNF-α 和 IL-1β,而 SOD 和 GSH 则显著增加。此外,木瓜碱还能上调 Fxr 基因、胆盐输出泵(Besp)、小异二聚体伙伴(shp)、肝细胞核因子 1α (Hnfα)、红细胞核因子 2 相关因子(Nrf2)、血红素加氧酶(Ho-1)、NAD(P)H 醌氧化还原酶 1(Nqo1)的表达。此外,木瓜碱还能增加大鼠肝脏中Sirtuin1(SIRT 1)、FXR、HO-1和BSEP的蛋白表达量。罂粟碱的保护作用可能是由于激活了FXR信号通路。这些研究结果表明,木蝴蝶碱对ANIT诱导的胆汁淤积症具有保护作用。
{"title":"Papaverine attenuates the progression of alpha naphthylisothiocyanate induce cholestasis in rats","authors":"Doaa Adnan Atshan ,&nbsp;Munaf Hashim Zalzala","doi":"10.1016/j.crphar.2024.100177","DOIUrl":"https://doi.org/10.1016/j.crphar.2024.100177","url":null,"abstract":"<div><p>Cholestasis is a hepatobiliary condition that manifests as acute or chronic and results from disruptions in the bile flow, formation, or secretion processes. The Farnesoid X receptor (FXR) is a vital target for the therapy of cholestasis since it regulates BA homeostasis. Despite the discovery of multiple active FXR agonists, there are still no effective treatments for cholestasis. Papaverine is identified as an FXR agonist.This study investigates papaverine's efficacy and probable mechanism in protecting against alpha naphthylisothiocyanate (ANIT) induced cholestasis. Thirty male albino rats were divided into three groups, each with ten rats. Group I (control) rats were administered 1 mL/kg corn oil 48 h before sacrifice; group II rats were orally administered 100 mg/kg ANIT. Group III received a 200 mg/kg dosage of papaverine over seven consecutive days. A single dose of ANIT at a concentration of 100 mg/kg was orally administered on the fifth day; group II and III animals were euthanized 48 h after inducing cholestasis, and serum concentrations of liver function tests and total bile acid (TBA) were measured. Besides measuring the inflammatory mediator's tumor necrosis factor-alpha (TNF-α) and interleukin 1 (IL-1β), antioxidant markers such as superoxide dismutase (SOD) and glutathione (GSH) were also assessed. The findings indicated the enhancement in the liver function test and total bile acids, as well as in liver histology; papaverine significantly lowered TNF-α and IL-1β while SOD and GSH significantly increased. Additionally, papaverine upregulates <em>Fxr</em> gene expression, bile salt export pump (<em>Besp</em>), small heterodimer partner (<em>shp</em>), hepatocyte nuclear factor 1α (<em>Hnfα</em>), nuclear factor erythroid 2-related factor (<em>Nrf2</em>), heme oxygenase (<em>Ho-1</em>), NAD(P)H quinone oxidoreductase 1 (<em>Nqo1</em>). Furthermore, papaverine increased protein expressions of Sirtuin1.</p><p>(SIRT 1), FXR, HO-1, and BSEP levels in the rats' livers. The protective effects of papaverine may be attributed to the activation of FXR signaling pathways. These findings revealed that papaverine protects against ANIT-induced Cholestasis.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"6 ","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259025712400004X/pdfft?md5=7649143687736ada6e8a2ab879020a7e&pid=1-s2.0-S259025712400004X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GERD: Latest update on acid-suppressant drugs 胃食管反流病抑酸药物的最新进展
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100198
Zyad AL-Frejat , Nafiza Martini , Alia Esper , Diana Al-Frejat , Samer Younes , Majd Hanna

GERD is a very familiar diagnosis among health care providers due to its massive spread, and its symptoms can affect the quality of life for a respectable slice of its patients. Therefore, what can only be described as a logical consequence, a pursuit of a treatment that can both relieve symptoms and have minimal side effects is still ongoing to cover the large demographic affected by GERD. In the following review, analysis will be made of GERD, including possible regulatory activity, of certain drugs to the already discussed pathways involved in GERD patients.

胃食管反流病由于其广泛的传播性,在医疗服务提供者中是一个非常熟悉的诊断,其症状会影响相当一部分患者的生活质量。因此,为了覆盖受胃食管反流病影响的广大人群,人们仍在不断寻求一种既能缓解症状又能将副作用降到最低的治疗方法,这可以说是顺理成章的事情。在下面的综述中,我们将对胃食管反流病进行分析,包括某些药物可能对胃食管反流病患者的相关途径产生的调节作用。
{"title":"GERD: Latest update on acid-suppressant drugs","authors":"Zyad AL-Frejat ,&nbsp;Nafiza Martini ,&nbsp;Alia Esper ,&nbsp;Diana Al-Frejat ,&nbsp;Samer Younes ,&nbsp;Majd Hanna","doi":"10.1016/j.crphar.2024.100198","DOIUrl":"10.1016/j.crphar.2024.100198","url":null,"abstract":"<div><p>GERD is a very familiar diagnosis among health care providers due to its massive spread, and its symptoms can affect the quality of life for a respectable slice of its patients. Therefore, what can only be described as a logical consequence, a pursuit of a treatment that can both relieve symptoms and have minimal side effects is still ongoing to cover the large demographic affected by GERD. In the following review, analysis will be made of GERD, including possible regulatory activity, of certain drugs to the already discussed pathways involved in GERD patients.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"7 ","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000257/pdfft?md5=e6c868901ce49b17b1265e7cd2f8052c&pid=1-s2.0-S2590257124000257-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ferroptosis induces nucleolar stress as revealed by live-cell imaging using thioflavin T 使用硫黄素 T 进行活细胞成像显示铁突变诱导细胞核应激
Q2 Agricultural and Biological Sciences Pub Date : 2024-01-01 DOI: 10.1016/j.crphar.2024.100196
Yoko Hirata , Hiroshi Takemori , Kyoji Furuta , Yuji O. Kamatari , Makoto Sawada

Nucleolar stress induced by stressors like hypoxia, UV irradiation, and heat shock downregulates ribosomal RNA transcription, thereby impairing protein synthesis capacity and potentially contributing to cell senescence and various human diseases such as neurodegenerative disorders and cancer. Live-cell imaging of the nucleolus may be a feasible strategy for investigating nucleolar stress, but currently available nucleolar stains are limited for this application. In this study using mouse hippocampal HT22 cells, we demonstrate that thioflavin T (ThT), a benzothiazole dye that binds RNA with high affinity, is useful for nucleolar imaging in cells where RNAs predominate over protein aggregates. Nucleoli were stained with high intensity simply by adding ThT to the cell culture medium, making it suitable for use even in damaged cells. Further, ThT staining overlapped with specific nucleolar stains in both live and fixed cells, but did not overlap with markers for mitochondria, lysosomes, endoplasmic reticulum, and double-stranded DNA. Ferroptosis, an iron-dependent nonapoptotic cell death pathway characterized by lipid peroxide accumulation, reduced the number of ThT-positive puncta while endoplasmic reticulum stress did not. These findings suggest that ferroptosis is associated with oxidative damage to nucleolar RNA molecules and ensuing loss of nucleolar function.

缺氧、紫外线照射和热休克等应激源诱导的核极应激会降低核糖体 RNA 的转录,从而损害蛋白质合成能力,并可能导致细胞衰老和各种人类疾病,如神经退行性疾病和癌症。核小体的活细胞成像可能是研究核小体应激的一种可行策略,但目前可用的核小体染色剂在这方面的应用有限。在这项使用小鼠海马 HT22 细胞进行的研究中,我们证明了硫黄素 T(ThT)--一种能与 RNA 高亲和力结合的苯并噻唑染料--在 RNA 多于蛋白质聚集的细胞中可用于核小体成像。只需在细胞培养基中加入 ThT,核小体就能得到高强度染色,因此即使在受损细胞中也能使用。此外,在活细胞和固定细胞中,ThT 染色与特定的核染色重叠,但与线粒体、溶酶体、内质网和双链 DNA 标记不重叠。铁凋亡是一种以过氧化脂质积累为特征的铁依赖性非凋亡细胞死亡途径,它能减少 ThT 阳性点的数量,而内质网应激则不会。这些发现表明,铁卟啉中毒与核小体 RNA 分子的氧化损伤以及随之而来的核小体功能丧失有关。
{"title":"Ferroptosis induces nucleolar stress as revealed by live-cell imaging using thioflavin T","authors":"Yoko Hirata ,&nbsp;Hiroshi Takemori ,&nbsp;Kyoji Furuta ,&nbsp;Yuji O. Kamatari ,&nbsp;Makoto Sawada","doi":"10.1016/j.crphar.2024.100196","DOIUrl":"https://doi.org/10.1016/j.crphar.2024.100196","url":null,"abstract":"<div><p>Nucleolar stress induced by stressors like hypoxia, UV irradiation, and heat shock downregulates ribosomal RNA transcription, thereby impairing protein synthesis capacity and potentially contributing to cell senescence and various human diseases such as neurodegenerative disorders and cancer. Live-cell imaging of the nucleolus may be a feasible strategy for investigating nucleolar stress, but currently available nucleolar stains are limited for this application. In this study using mouse hippocampal HT22 cells, we demonstrate that thioflavin T (ThT), a benzothiazole dye that binds RNA with high affinity, is useful for nucleolar imaging in cells where RNAs predominate over protein aggregates. Nucleoli were stained with high intensity simply by adding ThT to the cell culture medium, making it suitable for use even in damaged cells. Further, ThT staining overlapped with specific nucleolar stains in both live and fixed cells, but did not overlap with markers for mitochondria, lysosomes, endoplasmic reticulum, and double-stranded DNA. Ferroptosis, an iron-dependent nonapoptotic cell death pathway characterized by lipid peroxide accumulation, reduced the number of ThT-positive puncta while endoplasmic reticulum stress did not. These findings suggest that ferroptosis is associated with oxidative damage to nucleolar RNA molecules and ensuing loss of nucleolar function.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"7 ","pages":"Article 100196"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257124000233/pdfft?md5=c1089fbc0a10fc2cfe01e0f9b383037a&pid=1-s2.0-S2590257124000233-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Research in Pharmacology and Drug Discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1